PT996468E - Conjugados de lectinas que se ligam a galactose e neurotoxinas de clostridio como analgesicos - Google Patents
Conjugados de lectinas que se ligam a galactose e neurotoxinas de clostridio como analgesicosInfo
- Publication number
- PT996468E PT996468E PT98946571T PT98946571T PT996468E PT 996468 E PT996468 E PT 996468E PT 98946571 T PT98946571 T PT 98946571T PT 98946571 T PT98946571 T PT 98946571T PT 996468 E PT996468 E PT 996468E
- Authority
- PT
- Portugal
- Prior art keywords
- galactose
- pain
- agents
- clostridary
- neurotoxins
- Prior art date
Links
- 102000004856 Lectins Human genes 0.000 title 1
- 108090001090 Lectins Proteins 0.000 title 1
- 229940035676 analgesics Drugs 0.000 title 1
- 239000000730 antalgic agent Substances 0.000 title 1
- 229930182830 galactose Natural products 0.000 title 1
- 239000002523 lectin Substances 0.000 title 1
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010055044 Tetanus Toxin Proteins 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 102000007563 Galectins Human genes 0.000 abstract 1
- 108010046569 Galectins Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9721189.0A GB9721189D0 (en) | 1997-10-08 | 1997-10-08 | Analgesic conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
PT996468E true PT996468E (pt) | 2003-09-30 |
Family
ID=10820129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT98946571T PT996468E (pt) | 1997-10-08 | 1998-10-07 | Conjugados de lectinas que se ligam a galactose e neurotoxinas de clostridio como analgesicos |
Country Status (13)
Country | Link |
---|---|
US (2) | US7052702B1 (pt) |
EP (1) | EP0996468B1 (pt) |
JP (1) | JP4629225B2 (pt) |
AT (1) | ATE240747T1 (pt) |
AU (1) | AU741456B2 (pt) |
CA (1) | CA2306350C (pt) |
DE (1) | DE69814858T2 (pt) |
DK (1) | DK0996468T3 (pt) |
ES (1) | ES2198750T3 (pt) |
GB (1) | GB9721189D0 (pt) |
PT (1) | PT996468E (pt) |
WO (1) | WO1999017806A1 (pt) |
ZA (1) | ZA989138B (pt) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
US20080249019A1 (en) * | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
GB9907429D0 (en) * | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
WO2001014570A1 (en) | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
DE60008915T2 (de) * | 1999-12-02 | 2005-01-20 | Health Protection Agency, Salisbury | Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen |
US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
WO2001047512A2 (en) * | 1999-12-08 | 2001-07-05 | Fluoro Probe, Inc. | Method for relieving pain associated with an internal disease site |
US6641820B1 (en) * | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
CA2413301A1 (en) * | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
GB0108332D0 (en) * | 2001-04-03 | 2001-05-23 | Univ Durham | Lectin directed prodrug delivery system |
US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
GB0213383D0 (en) * | 2002-06-11 | 2002-07-24 | Cambridge Biotechnology Ltd | Therapeutic conditions |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7892565B2 (en) * | 2004-09-01 | 2011-02-22 | Allergan, Inc. | Degradable clostridial toxins |
US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US7659092B2 (en) | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
JP2008532549A (ja) * | 2005-03-15 | 2008-08-21 | アラーガン、インコーポレイテッド | 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素 |
US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
AU2007347781B2 (en) | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
US7993656B2 (en) | 2006-07-11 | 2011-08-09 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
RU2491086C2 (ru) * | 2007-10-23 | 2013-08-27 | Аллерган, Инк. | Способы лечения мочеполовых-неврологических расстройств с использованием модифицированных клостридиальных токсинов |
WO2011023213A1 (en) * | 2009-08-28 | 2011-03-03 | Merz Pharma Gmbh & Co. Kgaa | Modified chemodenervating agents |
GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
EP3372239B1 (en) | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
CN104870468B (zh) | 2012-11-21 | 2020-11-10 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
EP3822286A1 (en) | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
EP3274364B1 (en) | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
HUE064332T2 (hu) | 2016-10-20 | 2024-03-28 | Harvard College | In vitro és sejtalapú esszék botulinum neurotoxinok aktivitásának mérésére |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
CN111465352B (zh) | 2018-02-26 | 2024-04-12 | 益普生生物制药有限公司 | 使用超声波引导非细胞毒性蛋白酶的注射 |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
CA3211472A1 (en) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
WO2022208091A1 (en) | 2021-03-30 | 2022-10-06 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792447A (en) | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US4873346A (en) | 1985-09-20 | 1989-10-10 | The Upjohn Company | Substituted benzothiazoles, benzimidazoles, and benzoxazoles |
JPH05502880A (ja) | 1989-12-22 | 1993-05-20 | セラジェン・インコーポレーテッド | トランスロケーション領域および細胞結合領域を有するハイブリッド分子 |
AU1582692A (en) | 1991-03-08 | 1992-10-06 | Protein Design Labs, Inc. | Recombinant double chain immunotoxins |
WO1993004191A1 (en) | 1991-08-15 | 1993-03-04 | Neorx Corporation | Noncytolytic toxin conjugates |
US5433946A (en) | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
DE4242902A1 (de) | 1992-12-18 | 1994-06-23 | Madaus Ag | Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
DE69432299T2 (de) * | 1993-06-10 | 2003-12-11 | Allergan Inc | Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen |
EP1147775B1 (en) | 1993-12-28 | 2009-03-04 | Allergan, Inc. | Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder |
JP3497554B2 (ja) | 1994-03-25 | 2004-02-16 | 日本臓器製薬株式会社 | 新規プリン誘導体及びその薬学的に許容される塩 |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
AU695623B2 (en) | 1994-05-31 | 1998-08-20 | Allergan, Inc. | Modification of clostridial toxins for use as transport proteins |
GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
NZ337543A (en) | 1994-10-24 | 2002-06-28 | Allergan Inc | Composition comprising avian antitoxin against clostridial neurotoxin protein and method for producing recombinant antitoxin proteins are provided for |
US5721207A (en) * | 1995-04-18 | 1998-02-24 | Innapharma, Inc. | Method for treatment of pain |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
WO1997013410A1 (en) | 1995-10-13 | 1997-04-17 | Boston Medical Center Corporation | Hybrid molecules containing amidated polypeptide binding ligands |
CA2238262A1 (en) * | 1995-11-22 | 1997-05-29 | The Research And Development Institute, Inc. | Therapeutic and diagnostic agents for the treatment of microbial infections |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US5760149A (en) | 1996-08-23 | 1998-06-02 | Elf Atochem North America, Inc. | Poly(monoperoxycarbonates) |
EP1105153A4 (en) | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
DE19735105A1 (de) | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
JP4549533B2 (ja) | 1998-05-13 | 2010-09-22 | メルツ ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アオフ アクチェン | マスト細胞の脱顆粒を阻害するためのハイブリッドタンパク質とその使用 |
JP4454152B2 (ja) | 1998-07-22 | 2010-04-21 | オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド | 二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物 |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
GB9824282D0 (en) | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
-
1997
- 1997-10-08 GB GBGB9721189.0A patent/GB9721189D0/en not_active Ceased
-
1998
- 1998-10-07 DE DE69814858T patent/DE69814858T2/de not_active Expired - Lifetime
- 1998-10-07 JP JP2000514674A patent/JP4629225B2/ja not_active Expired - Fee Related
- 1998-10-07 US US09/529,130 patent/US7052702B1/en not_active Expired - Fee Related
- 1998-10-07 ZA ZA989138A patent/ZA989138B/xx unknown
- 1998-10-07 ES ES98946571T patent/ES2198750T3/es not_active Expired - Lifetime
- 1998-10-07 WO PCT/GB1998/003001 patent/WO1999017806A1/en active IP Right Grant
- 1998-10-07 PT PT98946571T patent/PT996468E/pt unknown
- 1998-10-07 DK DK98946571T patent/DK0996468T3/da active
- 1998-10-07 AT AT98946571T patent/ATE240747T1/de not_active IP Right Cessation
- 1998-10-07 CA CA002306350A patent/CA2306350C/en not_active Expired - Fee Related
- 1998-10-07 EP EP98946571A patent/EP0996468B1/en not_active Expired - Lifetime
- 1998-10-07 AU AU93574/98A patent/AU741456B2/en not_active Ceased
-
2005
- 2005-10-25 US US11/257,500 patent/US7452543B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20060121056A1 (en) | 2006-06-08 |
ATE240747T1 (de) | 2003-06-15 |
WO1999017806A1 (en) | 1999-04-15 |
ES2198750T3 (es) | 2004-02-01 |
CA2306350C (en) | 2008-09-02 |
DE69814858D1 (de) | 2003-06-26 |
JP2001518522A (ja) | 2001-10-16 |
JP4629225B2 (ja) | 2011-02-09 |
GB9721189D0 (en) | 1997-12-03 |
DE69814858T2 (de) | 2004-03-11 |
US7052702B1 (en) | 2006-05-30 |
EP0996468A1 (en) | 2000-05-03 |
ZA989138B (en) | 1999-05-27 |
CA2306350A1 (en) | 1999-04-15 |
AU741456B2 (en) | 2001-11-29 |
AU9357498A (en) | 1999-04-27 |
EP0996468B1 (en) | 2003-05-21 |
US7452543B2 (en) | 2008-11-18 |
DK0996468T3 (da) | 2003-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT996468E (pt) | Conjugados de lectinas que se ligam a galactose e neurotoxinas de clostridio como analgesicos | |
MXPA03000576A (es) | Motivo a base de leucina y neurotoxinas clostridial. | |
TR199701705T1 (xx) | Trigliserid ya�lar�n i�lenmesinde hareketsiz enzim ve kullan�m�. | |
PL323006A1 (en) | Derivatives of toxin clostridium capable to modify peripheral functions of afferent sensory fibres | |
ATE298791T1 (de) | Protease-varianten und zusammensetzungen | |
BR9608647A (pt) | Amilase dna e composição de detergente | |
AU7645100A (en) | Wound care device | |
DK1014954T3 (da) | Transdermalt terapeutisk system | |
DK0753057T3 (da) | Alkalisk Bacillus-amylase | |
WO2002044199A3 (en) | Neurotoxins with enhanced target specificity | |
ES2139369T5 (es) | Disposicion de bisagra con efecto resorte, por ejemplo para cierres de plastico inyectado de una sola pieza. | |
NL350034I1 (nl) | Pesticide tegen plantpathogene microorganismen | |
DK0456724T3 (da) | Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi | |
DE60028359D1 (de) | Chromogenes medium zum nachweis von staphylococcus aureus | |
ES2166010T3 (es) | Produccion de acrilato de amonio. | |
WO2000064405A3 (en) | Treating hair by targeting enzymes | |
PT1234043E (pt) | Construcoes para a entrega de agentes terapeuticos a celulas neuronais | |
AU2001282199A1 (en) | A tyrosinase enzyme | |
BR0115336A (pt) | Método para fabricar um produto fibroso celulósico, produto fibroso celulósico ligado, e, produto absorvente de cuidado pessoal | |
AU2813200A (en) | Assay for measuring different enzyme activities simultaneously | |
DE69610948D1 (de) | Immunoenzymatisches konjugat, herstellungsverfahren dafür und verwendungen | |
DE59605990D1 (de) | Anschlussvorrichtung für anschlagmittel | |
Sanchez | Mutalysins | |
DK177791D0 (da) | Tensidfrie, faste enzympraeparater omfattende protease som virksomt enzym | |
PT1196606E (pt) | Enzima litica |